Drug intelligence / Profile preview

Lianggan Qingxin Jiangya capsule

Development stage: Unknown
Lead developer: Post Construction of Taishan Scholars in Shandong Province
Administration: Oral

Overview

Lianggan Qingxin Jiangya capsule is a Traditional Chinese Medicine (TCM) formulation developed for the treatment of grade 1 essential hypertension with liver fire syndrome. It is administered orally as a capsule and is currently undergoing clinical evaluation in randomized, double-blind, placebo-controlled, multicenter clinical studies.

Other names: 凉肝清心降压胶囊

Beyond the preview

Go deeper on Lianggan Qingxin Jiangya capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lianggan Qingxin Jiangya capsule.

Explore the full profile